What are Allogene Therapeutics's total assets?

Allogene Therapeutics (ALLO) holds $396.0M in total assets, down 22.1% year over year.

How much debt does Allogene Therapeutics have?

Allogene Therapeutics carries $81.1M in total debt against $278.9M of shareholders' equity, a debt-to-equity ratio of 0.29.

How much cash does Allogene Therapeutics have?

Allogene Therapeutics holds $40.6M in cash and equivalents.

Can Allogene Therapeutics cover its short-term obligations?

Its current ratio is 9.65 — current assets exceed current liabilities.

Where does Allogene Therapeutics's balance sheet data come from?

Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Allogene Therapeutics ALLO Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Cash and cash equivalents	$40.6M-23.0%	$61.98M-27.5%	$48.11M-21.8%	$62.62M-65.4%	$52.75M-14.0%
Short-term investments	$236.58M-0.4%	$198.52M-8.6%	$214.38M-10.8%	$220.79M-19.4%	$237.59M-28.8%
Restricted cash	$10.29M0.0%	$10.29M0.0%	$10.29M0.0%	$10.29M0.0%	$10.29M0.0%
Prepaid expenses and other current assets	$6.41M-44.4%	$7.54M-30.9%	$8.53M-33.7%	$9.54M-23.7%	$11.53M+9.8%
Total current assets	$273.29M-6.3%	$257.75M-15.0%	$260.72M-14.4%	$282.66M-38.2%	$291.58M-26.3%
Property and equipment, net	$70.02M-15.6%	$72.84M-15.4%	$75.9M-14.7%	$78.86M-14.4%	$82.99M-13.5%
Accumulated depreciation	$75.4M+14.9%	$72.53M+16.0%	$69.51M+16.7%	$66.96M+18.8%	$65.64M+20.1%
Operating lease right-of-use assets	6.5%+0.2%	3,988,800,000%-531,700,000%	6.3%0.0%	6.3%0.0%	6.3%0.0%
Other non-current assets	$3.53M+85.8%	$3.62M+55.5%	$3.51M-29.3%	$3.83M-40.5%	$1.9M-63.2%
Available-for-sale securities	$0-100%	$8.04M-90.0%	$24.94M-77.7%	$29.51M—	$55.51M+347%
Total assets	$395.96M-22.1%	$415.91M-24.2%	$439.77M-25.4%	$470.59M-27.3%	$507.98M-13.4%
Accounts payable	$4.93M-2.5%	$4.27M-20.8%	$3.7M-32.8%	$4.85M-62.5%	$5.06M-12.5%
Operating lease liabilities, current	$8.42M+10.3%	$8.21M+9.3%	$8.01M+8.4%	$7.76M+7.4%	$7.63M+10.1%
Accrued interest	$1.3M-43.5%	$1.5M-21.1%	$2.1M-25.0%	$1.7M-15.0%	$2.3M+35.3%
Total current liabilities	$28.33M-5.6%	$32.51M-8.5%	$31.83M-2.3%	$31.68M-15.1%	$30.02M-2.8%
Operating lease liabilities, non-current	$72.63M-10.7%	$75.05M-9.9%	$77.13M-9.4%	$79.24M-8.9%	$81.29M-8.6%
Operating Lease Liabilities (Total)	$81.05M-8.9%	$83.25M-8.3%	$85.14M-8.0%	$87M-7.7%	$88.92M-7.2%
Other non-current liabilities	$16.12M+43.0%	$15.8M+104%	$15.48M+102%	$15.12M+100%	$11.28M+118%
Total liabilities	$117.08M-4.5%	$123.36M-2.5%	$124.44M-0.7%	$126.03M-4.4%	$122.59M-1.9%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	400M0.0%	400M+188,579%	400M0.0%	400M0.0%	400M0.0%
Additional paid-in capital	$2.33B+3.0%	$2.3B+2.7%	$2.29B+2.9%	$2.27B+3.0%	$2.26B+8.4%
Retained earnings	-$2.05B-9.2%	-$2.01B-10.5%	-$1.97B-12.0%	-$1.93B-14.0%	-$1.88B-15.5%
Accumulated other comprehensive income (loss)	-$183K-526%	$269K+402%	$235K+49.7%	-$45K+94.2%	$43K+105%
Total stockholders' equity	$278.88M-27.6%	$292.54M-30.7%	$315.33M-32.0%	$344.56M-33.1%	$385.39M-16.5%
Total liabilities and stockholders' equity	$395.96M-22.1%	$415.91M-24.2%	$439.77M-25.4%	$470.59M-27.3%	$507.98M-13.4%
Available-for-Sale Debt Securities - Amortized Cost	$261.82M-20.9%	$254.87M-30.9%	$270.69M-31.6%	$301.13M-30.9%	$331.19M-15.5%
AFS and Trading Securities - Unrealized Loss Position Fair Value	$0—	$0—	$2.5M—	$0-100%	$0-100%
Cash, Cash Equivalents, and Marketable Securities	$0—	$0—	$2.5M—	$0-100%	$0-100%
Available For Sale Securities Debt Securities Current	$236.58M-0.4%	$198.52M-8.6%	$214.38M-10.8%	$220.79M-19.4%	$237.59M-28.8%
Cash Cash Equivalents And Short Term Investments	$266.9M-20.4%	——	$277.1M-31.3%	$302.6M-31.9%	$335.5M-15.6%
Deferred Tax Assets and Other Non-Current Assets	$3.53M+85.8%	$3.62M+55.5%	$3.51M-29.3%	$3.83M-40.5%	$1.9M-63.2%
Investments - Amortized Cost Basis	$261.82M-20.9%	$254.87M-30.9%	$270.69M-31.6%	$301.13M-30.9%	$331.19M-15.5%
Net Investment in Lease	$38.82M-11.9%	$39.89M-11.8%	$40.94M-11.6%	$41.97M-28.1%	$44.08M-31.6%
Long-term marketable securities	$0-100%	$8.04M-90.0%	$24.94M-77.7%	$29.51M—	$55.51M+347%
Operating lease right-of-use assets	$38.82M-11.9%	$39.89M-11.8%	$40.94M-11.6%	$41.97M-28.1%	$44.08M-31.6%
Other non-current assets	$3.53M+85.8%	$3.62M+55.5%	$3.51M-29.3%	$3.83M-40.5%	$1.9M-63.2%
Property, plant and equipment at cost	$145.43M-2.2%	$145.37M-2.2%	$145.41M-2.1%	$145.82M-1.8%	$148.63M-1.3%
Operating Lease Right-of-Use Assets in Other Assets	$38.82M-11.9%	$39.89M-11.8%	$40.94M-11.6%	$41.97M-28.1%	$44.08M-31.6%
Software and Technology Licenses, Net	$3.53M+85.8%	$3.62M+55.5%	$3.51M-29.3%	$3.83M-40.5%	$1.9M-63.2%
Commercial Paper Outstanding	$6M0.0%	$6M0.0%	$6M0.0%	$6M0.0%	$6M0.0%
Accrued and other current liabilities	$23.4M-6.3%	$28.24M-6.3%	$28.13M+3.9%	$26.82M+10.1%	$24.96M-0.3%
Lease Liability Payments - 2020 (Remaining Three Months)	$9.9M+2.1%	——	$3.21M+0.3%	$6.4M+0.3%	$9.69M+2.7%
Operating Lease Liability Payments - 2024 (Lessee)	$14.04M+3.1%	——	$13.61M+3.4%	$13.61M+3.4%	$13.61M+3.4%
Operating Lease Liability Payments - 2025 (Lessee)	$16.15M+4.3%	——	$15.48M+10.0%	$15.48M+10.0%	$15.48M+10.0%
Lease Liability Payments - Due Year Two	$14.04M+3.1%	——	$13.61M+3.4%	$13.61M+3.4%	$13.61M+3.4%
Lease Liability Payments - Due Year Three	$15.44M+9.6%	——	$14.08M+3.4%	$14.08M+3.4%	$14.08M+3.4%
Lease Liability Payments - Due Year Four	$16.15M+4.3%	——	$15.48M+10.0%	$15.48M+10.0%	$15.48M+10.0%
Lease Liability Payments - Remainder of Fiscal Year	$13.57M+3.1%	——	$13.16M+1.9%	$13.16M+1.9%	$13.16M+1.9%
Operating Lease Liability Payments Due	$102.69M-11.4%	——	$109.45M-10.5%	$112.65M-10.3%	$115.94M-9.8%
Operating Lease Liability - Undiscounted Excess Amount	$21.64M-19.9%	——	$24.31M-18.5%	$25.65M-18.1%	$27.02M-17.5%
Operating Lease Liability Payments - 2027 (Lessee)	$15.44M+9.6%	——	$14.08M+3.4%	$14.08M+3.4%	$14.08M+3.4%
Operating Lease Liability Payments - 2028 (Lessee)	$16.15M+4.3%	——	$15.48M+10.0%	$15.48M+10.0%	$15.48M+10.0%
Total debt	$81.05M-8.9%	$83.25M-8.3%	$85.14M-8.0%	$87M-7.7%	$88.92M-7.2%
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	244.8M+12.0%	229.4M+8.1%	223.2M+6.5%	220.1M+5.3%	218.6M+28.2%
Convertible Preferred Stock Authorized Shares	10M0.0%	10M0.0%	10M0.0%	10M0.0%	10M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—	0—
Additional paid-in capital	$2.33B+3.0%	$2.3B+2.7%	$2.29B+2.9%	$2.27B+3.0%	$2.26B+8.4%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$245K+11.9%	$229K+8.0%	$223K+6.2%	$220K+5.3%	$219K+28.8%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Investments - Gross Unrealized Losses	$0—	$0—	$2.5M—	$0-100%	$0-100%
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Shares Reserved for Future Issuance Under Stock Plans	9M+72.5%	——	6.8M-28.2%	5.9M-39.9%	5.2M-46.6%
Unrealized Gains on Investments	$66K-53.2%	$279K+84.8%	$250K-59.5%	$71K+689%	$141K+303%
Unrealized Losses on Investments (Before Tax)	$249K+154%	$10K-95.8%	$15K-16.7%	$116K-66.4%	$98K-81.1%
Cumulative Cost Basis	$261.82M-20.9%	$254.87M-30.9%	$270.69M-31.6%	$301.13M-30.9%	$331.19M-15.5%
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$249K+154%	$10K-95.8%	$15K-16.7%	$116K-66.4%	$98K-81.1%
Gross Unrealized Gains	$66K-53.2%	$279K+84.8%	$250K-59.5%	$71K+689%	$141K+303%
Total	$261.82M-20.9%	$254.87M-30.9%	$270.69M-31.6%	$301.13M-30.9%	$331.19M-15.5%
Available for sale investments	$261.63M-21.0%	$255.14M-30.8%	$270.92M—	$301.09M—	$331.23M—
Cash Equivalents And Short Term Investments	$261.63M-21.0%	$255.14M-30.8%	$270.92M-31.6%	$301.09M-30.9%	$331.23M-15.3%
Common stock, capital shares reserved for future issuance	$8.96M+72.5%	——	$6.83M-28.2%	$5.9M-39.9%	$5.2M-46.6%
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$400M0.0%	$400M0.0%	$400M0.0%	$400M0.0%	$400M0.0%
Common stock, shares issued (in shares)	$244.82M+12.0%	$229.41M+8.1%	$223.16M+6.5%	$220.13M+5.3%	$218.6M+28.2%
Common Stock, Shares, Outstanding	$244.82M+12.0%	$229.41M+8.1%	$223.16M+6.5%	$220.13M+5.3%	$218.6M+28.2%
Debt Securities, Available-for-Sale, Unrealized Loss Position	$0—	$0—	$2.5M—	$0-100%	$0-100%
Escrow deposit	$0-100%	$23.48M+13.0%	$23.47M+5.2%	$23.48M+9.6%	$21.64M—
Termination payment	——	——	——	——	——
Lessee Operating Lease Liability Payments Due	$102.69M-11.4%	——	$109.45M-10.5%	$112.65M-10.3%	$115.94M-9.8%
2031 and thereafter	$33.6M-32.7%	——	$49.91M-23.7%	$49.91M-23.7%	$49.91M-23.7%
Lessee Operating Lease Liability Undiscounted Excess Amount	$21.64M-19.9%	——	$24.31M-18.5%	$25.65M-18.1%	$27.02M-17.5%
Letters of Credit Outstanding, Amount	$6M0.0%	$6M0.0%	$6M0.0%	$6M0.0%	$6M0.0%
Operating Lease Weighted Average Discount Rate Percent	$0.07+3.8%	——	$0.06+0.5%	$0.06+0.5%	$0.06+0.3%
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$10M0.0%	$10M0.0%	$10M0.0%	$10M0.0%	$10M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—	$0—
Stock issuance, maximum compensation due to third party, percent	——	——	——	——	——
Remainder of Fiscal Year 2024	$9.9M+2.1%	——	$3.21M+0.3%	$6.4M+0.3%	$9.69M+2.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Allogene Therapeutics's total assets?: Allogene Therapeutics (ALLO) holds $396.0M in total assets, down 22.1% year over year.
How much debt does Allogene Therapeutics have?: Allogene Therapeutics carries $81.1M in total debt against $278.9M of shareholders' equity, a debt-to-equity ratio of 0.29.
How much cash does Allogene Therapeutics have?: Allogene Therapeutics holds $40.6M in cash and equivalents.
Can Allogene Therapeutics cover its short-term obligations?: Its current ratio is 9.65 — current assets exceed current liabilities.
Where does Allogene Therapeutics's balance sheet data come from?: Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.